The agency green lit teplizumab (brand name Tzield) for children 8 and older with stage 3 type 1 diabetes on Friday, but the path to yes included a center director overruling her own reviewers, a sponsor asking to exit a new speedy review program, and a missed agency goal date.
The FDA on Friday approved Sanofi's teplizumab for children 8 and older with stage 3 type 1 diabetes, but the clean headline hides an unusually jagged approval process: the agency's top drug official disagreed with her own reviewers, the sponsor asked to leave the new speedy review program, and the regulator missed its own April 21 decision deadline.
The drug, sold as Tzield, is an anti-CD3 therapy that delays the immune system's attack on insulin-producing cells, buying time before a patient becomes dependent on insulin. The June 12 approval, reported first by STAT, extends the drug's label to children in stage 3 type 1 diabetes, the early symptomatic stage that follows the pre-clinical stage 2 window in which teplizumab was first authorized.
What makes the decision consequential is not the drug itself but the institutional choreography around it. Teplizumab had been picked for the speedier review program launched last year by then-Commissioner Marty Makary, an initiative meant to shorten timelines for therapies the agency considered high-priority. The FDA then missed its own April 21 goal date for a decision under that program.
Inside the FDA's Center for Drug Evaluation and Research, the career scientists who reviewed the application recommended approval. Tracy Beth Høeg, who was serving as CDER's center director and is a political appointee from the Makary era, disagreed with that recommendation, an unusually public center-director override on a single application. According to prior STAT reporting, Sanofi subsequently asked to withdraw teplizumab from the speedier review program in the wake of Høeg's intervention. The agency approved the drug anyway.
A center director's authority to overrule a review division is structural, not personal: CDER's review teams generate a recommendation, the office director signs off, and the center director has final say. Staff overrides at that level are rare, and they tend to draw scrutiny because they test the line between political leadership and scientific judgment. Høeg's departure from CDER, after the override but before the approval became public, sharpens that question: the record is now permanent, even if her tenure is not.
Sanofi's decision to ask out of the program is the other half of the story. Sponsors do not usually request to leave a speedier review pathway once they are in it, because the trade is supposed to be faster access in exchange for tighter timelines and closer agency engagement. That Sanofi asked to exit, and that the FDA still approved the drug, suggests the program is being stress-tested on its first high-profile pediatric application in ways its architects did not anticipate.
The clinical stakes remain concrete. Stage 3 type 1 diabetes is the point at which the immune system has begun destroying the beta cells that make insulin, often producing symptoms but not yet full insulin dependence. Delaying progression by even a year can change the shape of childhood with the disease, and pediatricians have had limited disease-modifying tools to offer families. Teplizumab's prior approval, in stage 2, was a landmark; the stage 3 expansion gives clinicians a second, later window.
What to watch next: whether the FDA explains the override in any post-decision documentation, whether Sanofi publicly reconfirms its commitment to the speedy review program on future submissions, and how Makary's successor handles the next time a center director and a review division disagree on the merits. The first visible test of a signature regulatory program rarely settles the questions it raises. It usually sharpens them.